Zacks: Brokerages Expect Glaukos Corp (GKOS) Will Announce Earnings of -$0.12 Per Share
Wall Street analysts expect Glaukos Corp (NYSE:GKOS) to announce earnings per share (EPS) of ($0.12) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Glaukos’ earnings. The lowest EPS estimate is ($0.18) and the highest is ($0.07). Glaukos posted earnings of ($0.08) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 50%. The firm is expected to issue its next quarterly earnings results on Wednesday, May 8th.
According to Zacks, analysts expect that Glaukos will report full-year earnings of ($0.33) per share for the current financial year, with EPS estimates ranging from ($0.40) to ($0.18). For the next financial year, analysts anticipate that the firm will report earnings of $0.02 per share, with EPS estimates ranging from ($0.17) to $0.21. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Glaukos.
Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, February 27th. The medical instruments supplier reported $0.04 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.17. Glaukos had a negative net margin of 7.14% and a negative return on equity of 8.24%. The firm had revenue of $54.08 million during the quarter, compared to the consensus estimate of $49.60 million. During the same period last year, the firm earned $0.03 EPS. The business’s quarterly revenue was up 29.8% compared to the same quarter last year.
Shares of NYSE GKOS traded down $3.90 during mid-day trading on Wednesday, reaching $76.03. 406,724 shares of the company were exchanged, compared to its average volume of 402,224. Glaukos has a 52 week low of $26.75 and a 52 week high of $83.14. The company has a market capitalization of $2.89 billion, a P/E ratio of -205.49 and a beta of 1.63.
In related news, COO Chris M. Calcaterra sold 90,000 shares of Glaukos stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $67.69, for a total value of $6,092,100.00. Following the transaction, the chief operating officer now owns 193,344 shares in the company, valued at approximately $13,087,455.36. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Joseph E. Gilliam sold 5,000 shares of Glaukos stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $70.03, for a total transaction of $350,150.00. The disclosure for this sale can be found here. Insiders own 11.60% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. Capital World Investors raised its position in Glaukos by 1.0% in the 3rd quarter. Capital World Investors now owns 2,820,000 shares of the medical instruments supplier’s stock worth $183,018,000 after purchasing an additional 27,519 shares during the period. Vanguard Group Inc. raised its position in Glaukos by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,805,222 shares of the medical instruments supplier’s stock worth $182,059,000 after purchasing an additional 90,235 shares during the period. Vanguard Group Inc raised its position in Glaukos by 3.3% in the 3rd quarter. Vanguard Group Inc now owns 2,805,222 shares of the medical instruments supplier’s stock worth $182,059,000 after purchasing an additional 90,235 shares during the period. BlackRock Inc. raised its position in Glaukos by 6.3% in the 4th quarter. BlackRock Inc. now owns 2,563,895 shares of the medical instruments supplier’s stock worth $144,014,000 after purchasing an additional 151,304 shares during the period. Finally, FMR LLC raised its position in Glaukos by 85.8% in the 4th quarter. FMR LLC now owns 2,280,178 shares of the medical instruments supplier’s stock worth $128,077,000 after purchasing an additional 1,052,748 shares during the period.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.
See Also: What is a capital gain?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.